KR20170141812A - Ｄｐｐ ｉｖ 억제제 제형 - Google Patents

Ｄｐｐ ｉｖ 억제제 제형 Download PDF

Info

Publication number
KR20170141812A
KR20170141812A KR1020177035865A KR20177035865A KR20170141812A KR 20170141812 A KR20170141812 A KR 20170141812A KR 1020177035865 A KR1020177035865 A KR 1020177035865A KR 20177035865 A KR20177035865 A KR 20177035865A KR 20170141812 A KR20170141812 A KR 20170141812A
Authority
KR
South Korea
Prior art keywords
weight
pharmaceutical composition
diluent
lubricant
composition according
Prior art date
Application number
KR1020177035865A
Other languages
English (en)
Other versions
KR102051281B1 (ko
Inventor
안야 콜라우쉬
패트릭 로머
게르트 자이페르트
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36972901&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170141812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20170141812A publication Critical patent/KR20170141812A/ko
Application granted granted Critical
Publication of KR102051281B1 publication Critical patent/KR102051281B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

본 발명은 아미노 그룹을 갖는 DPP IV 억제제로 이루어진 약제학적 조성물, 이의 제조방법, 및 진성 당뇨병의 치료를 위한 이의 용도에 관한 것이다.

Description

ＤＰＰ ＩＶ 억제제 제형 {DPP IV inhibitor formulations}
본 발명은 선택된 DPP IV 억제제로 이루어진 약제학적 조성물, 이의 제조방법, 및 선택된 의학적 상태의 치료를 위한 이의 용도에 관한 것이다.
CD26으로도 공지되어 있는 효소 DPP-IV (디펩티딜 펩티다아제 IV (dipeptidyl peptidase IV))는, N-말단에 프롤린 또는 알라닌 잔기를 갖는 다수의 단백질의 N-말단으로부터 디펩티드를 개열시키는 것으로 공지되어 있는, 세린 프로테아제이다. 이의 특성으로 인하여, 펩티트 GLP-1을 포함하는 생활성 펩티드의 혈장 농도를 간섭하는 DPP-IV 억제제가, 장래성 있는 진성 당뇨병 치료 약물인 것으로 간주된다.
선택된 DPP-IV 억제제의 약제학적 조성물을 제조하기 위한 시도에서, 1급 또는 2급 아미노 그룹을 갖는 DPP-IV 억제제는 미세결정질 셀룰로오스, 나트륨 전분 글리콜레이트, 크로스카멜로오스 나트륨, 타르타르산, 시트르산, 글루코오스, 프럭토오스, 사카로오스, 락토오스, 말토덱스트린과 같은 다수의 통상의 부형제와 비혼화성, 열화 문제, 또는 추출 문제를 나타내는 것으로 관찰되어 왔다. 화합물 자체가 매우 안정할지라도, 당해 화합물은, 고체 투여 제형에 사용되는 다수의 부형제와 반응하며, 특히 정제에서 제공되는 밀착 접촉 및 높은 부형제/약물 비율에서 부형제의 불순물과 반응한다. 아미노 그룹은 환원 당과 반응하고, 기타 반응성 카보닐 그룹과 반응하고, 예를 들면, 산화에 의해 미세결정질 셀룰로오스의 표면에 형성된 카복실산 작용기와 반응하는 것으로 보인다. 이러한 예측하지 못하는 어려움들은, 선택된 억제제의 놀라운 효능으로 인하여 요구되는 낮은 투여 범위에서 주로 관찰된다. 따라서, 선택된 DPP-IV 억제제 화합물의 예상치 못한 효능과 관련된 이들 기술적인 문제들을 해결하기 위한 약제학적 조성물이 요구된다.
본 발명에 따르는 약제학적 조성물은 1형 또는 2형 진성 당뇨병 환자의 혈당 조절을 달성하기 위한 치료를 위한 것이며, 활성 성분으로서의 아미노 그룹, 특히 유리 (free) 또는 1급 아미노 그룹을 갖는 DPP-IV 억제제, 제1 및 제2 희석제, 결합제, 붕해제 및 윤활제를 포함한다. 추가의 붕해제 및 추가의 활제 (glidant)는 추가의 선택 사항이다. 추가로, 당해 조성물은 류머티즘성 관절염, 비만증 및 골다공증의 치료 및 동종 이식 (allograft transplantation)의 지원에 사용될 수 있다.
본 발명에 따르는 약제학적 조성물에 적합한 희석제로는 셀룰로오스 분말, 2염기성 인산칼슘 무수물, 2염기성 인산칼슘 2수화물, 에리트리톨, 저치환된 하이드록시프로필 셀룰로오스, 만니톨, 프리젤라틴화 (pregelatinized) 전분 또는 자일리톨이 있다. 이들 희석제들 중에서, 만니톨 및 프리젤라틴화 전분이 바람직하다.
제2 희석제로서 바람직한 희석제로는, 추가의 결합제 특징을 갖는 위에서 언급된 희석제 프리젤라틴화 전분 및 저치환된 하이드록시프로필셀룰로오스 (L-HPC)가 있다.
본 발명에 따르는 약제학적 조성물에 적합한 윤활제로는 활석, 폴리에틸렌글리콜, 베헨산칼슘, 스테아르산칼슘, 수소화 피마자유 또는 스테아르산마그네슘이 있다. 바람직한 윤활제는 스테아르산마그네슘이다.
본 발명에 따르는 약제학적 조성물에 적합한 결합제로는 코포비돈 (비닐피롤리돈의 다른 비닐유도체와의 공중합물), 하이드록시프로필 메틸셀룰로오스 (HPMC), 하이드록시프로필셀룰로오스 (HPC), 폴리비닐피롤리돈 (포비돈), 프리젤라틴화 전분, 저치환된 하이드록시프로필셀룰로오스 (L-HPC)이 있으며, 코포비돈 및 프리젤라틴화 전분이 바람직하다.
위에서 언급된 결합제 프리젤라틴화 전분 및 L-HPC는 추가의 희석제 및 붕해제 특징을 나타내며, 제2 희석제 또는 붕해제로서 사용될 수도 있다.
본 발명에 따르는 약제학적 조성물에 적합한 붕해제로는 옥수수 전분, 크로스포비돈, 저치환된 하이드록시프로필셀룰로오스 (L-HPC) 또는 프리젤라틴화 전분이 있으며, 옥수수 전분이 바람직하다.
임의의 활제로서 콜로이드성 이산화규소가 사용될 수 있다.
본 발명에 따라는 예시적인 조성물은 희석제 만니톨, 추가의 결합제 특징을 갖는 희석제로서의 프리젤라틴화 전분, 결합제 코포비돈, 붕해제 옥수수 전분, 및 윤활제로서의 스테아르산마그네슘을 포함한다.
본 발명에 따르는 약제학적 조성물로 제조된 투여 제형은 활성 성분을 0.1 내지 100mg의 투여 범위로 함유한다. 바람직한 투여량은 0.5mg, 1mg, 2.5mg, 5mg 및 10mg이다.
통상의 약제학적 조성물은
활성 성분 0.5 내지 20중량%,
제1 희석제 40 내지 88중량%,
제2 희석제 3 내지 40중량%,
결합제 1 내지 5중량%,
붕해제 5 내지 15중량% 및
윤활제 0.1 내지 4중량%를 포함한다.
바람직한 약제학적 조성물은
활성 성분 0.5 내지 7중량%,
제1 희석제 50 내지 75중량%,
제2 희석제 5 내지 15중량%,
결합제 2 내지 4중량%,
붕해제 8 내지 12중량% 및
윤활제 0.5 내지 2중량%를 포함한다.
본 발명에 따르는 약제학적 조성물은 경구 사용을 위한 것이며, 캡슐제, 정제 또는 필름-피복 정제의 투여 제형으로 사용될 수 있다. 통상적으로, 필름 피복물은 당해 조성물 2 내지 4%, 바람직하게는 3%로 이루어지며, 필름-형성제, 가소제, 활제 및 임의로 하나 이상의 안료를 포함한다. 예시적인 피복 조성물은 하이드록시프로필메틸-셀룰로오스 (HPMC), 폴리에틸렌 글리콜 (PEG), 활석, 이산화티탄 및 임의로 산화철을 포함할 수 있다.
본 발명의 맥락에서 바람직한 활성 성분은 1급 아미노 그룹을 갖는 DPP-IV 억제제 및 이의 염, 예를 들면, 화학식 I 또는 화학식 II로 정의되는 임의의 DPP-IV 억제제 및 이의 염이다.
[화학식 I]
Figure pat00001
[화학식 II]
Figure pat00002
위의 화학식 I 및 화학식 II에서,
R1은 ([1,5]나프티리딘-2-일)메틸, (퀴나졸린-2-일)메틸], (퀴녹살린-6-일)메틸, (4-메틸-퀴나졸린-2-일)메틸, 2-시아노-벤질, (3-시아노-퀴놀린-2-일)메틸, (3-시아노-피리딘-2-일)메틸, (4-메틸-피리미딘-2-일)메틸 또는 (4,6-디메틸-피리미딘-2-일)메틸이고,
R2는 3-(R)-아미노-피페리딘-1-일, (2-아미노-2-메틸-프로필)-메틸아미노 또는 (2-(S)-아미노-프로필)-메틸아미노이다.
바람직한 DPP　IV 억제제 화합물은 다음의 화합물 및 이의 염이다.
ㆍ 1-[(4-메틸-퀴나졸린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-(3-(R)-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2004/018468호, 실시예 2(142)와 비교):
Figure pat00003
ㆍ 1-[([1,5]나프티리딘-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2004/018468호, 실시예 2(252)와 비교):
Figure pat00004
ㆍ 1-[(퀴나졸린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2004/018468호, 실시예 2(80)와 비교):
Figure pat00005
ㆍ 2-((R)-3-아미노-피페리딘-1-일)-3-(부트-2-이닐)-5-(4-메틸-퀴나졸린-2-일메틸)-3,5-디하이드로-이미다조[4,5-d]피리다진-4-온(국제 공개공보 제WO 2004/050658호, 실시예 136와 비교):
Figure pat00006
ㆍ 1-[(4-메틸-퀴나졸린-2-일)메틸]-3-메틸-7-(2-부티인-1-일)-8-[(2-아미노-2-메틸-프로필)-메틸아미노]-크산틴(국제 공개공보 제WO 2006/029769호, 실시예 2(1)와 비교):
Figure pat00007
ㆍ 1-[(3-시아노-퀴놀린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(30)와 비교):
Figure pat00008
ㆍ 1-(2-시아노-벤질)-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(39)와 비교):
Figure pat00009
ㆍ 1-[(4-메틸-퀴나졸린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-[(S)-(2-아미노-프로필)-메틸아미노]-크산틴(국제 공개공보 제WO 2006/029769호, 실시예 2(4)와 비교):
Figure pat00010
ㆍ 1-[(3-시아노-피리딘-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(52)와 비교):
Figure pat00011
ㆍ 1-[(4-메틸-피리미딘-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(81)와 비교):
Figure pat00012
ㆍ 1-[(4,6-디메틸-피리미딘-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(82)와 비교):
Figure pat00013
ㆍ 1-[(퀴녹살린-6-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-((R)-3-아미노-피페리딘-1-일)-크산틴(국제 공개공보 제WO 2005/085246호, 실시예 1(83)와 비교):
Figure pat00014
본 발명에 따르는 조성물을 제조하기 위해, 과립제를 습식 과립화 공정에 의해 제조할 수 있다. 액체 과립화는 동반한, 활성 성분 및 부형제의 또 다른 과립화 방법으로는, 유동층 과립화 또는 단일용기 (one-pot) 과립화가 있다.
습식 과립화 공정에서, 과립화 액체는 물, 에탄올, 메탄올, 이소프로판올, 아세톤, 바람직하게는 정제수와 같은 용매이며, 코포비돈과 같은 결합제를 함유한다. 당해 용매는, 최종 생성물에 남아있지 않는 휘발성 성분이다. 윤활제를 제외한 기타 부형제 및 활성 성분은 예비혼합되고, 고전단 과립화기를 사용하여 수성 과립화 액체와 함께 과립화된다. 습식 과립화 단계에 이어서, 임의의 습식 체질 (sieving) 단계, 건조 단계, 및 과립의 체질 단계가 수행된다. 예를 들면, 건조를 목적으로 유동층 건조기가 사용될 수 있다.
건조된 과립은 적절한 체 (sieve)를 통해 체질된다. 윤활제를 제외한 기타 부형제를 첨가한 후에, 당해 혼합물을 자유 낙하 블렌더 (free fall blender)와 같은 적합한 통상의 블렌더로 블렌딩하고, 이어서 스테아르산마그네슘과 같은 윤활제를 첨가하고, 블렌더로 최종 블렌딩한다.
따라서, 본 발명에 따르는 약제학적 조성물의 제조를 위한 예시적인 습식 과립화 공정은
a. 상온에서 코포비돈과 같은 결합제를 정제수와 같은 용매에 용해시켜, 과립화 액체를 제조하는 단계;
b. DPP-IV 억제제, 희석제 및 붕해제를 적합한 혼합기에서 블렌딩하여, 프리믹스 (premix)를 제조하는 단계;
c. 당해 프리믹스를 과립화 액체로 습윤시키고, 후속적으로 당해 습윤된 프리믹스를, 예를 들면, 고전단 믹서에서 과립화시키는 단계;
d. 당해 과립화된 프리믹스를 적어도 1.0mm, 바람직하게는 3mm의 메쉬 크기를 갖는 체를 통해 임의로 체질하는 단계;
e. 당해 과립제를, 약 40 내지 75℃, 바람직하게는 55 내지 65℃의 불활성 공기 온도에서, 예를 들면, 유동층 건조기에서, 1 내지 5% 범위의 목적하는 건조 감량이 수득될 때까지 건조시키는 단계;
f. 당해 건조된 과립제를, 예를 들면, 0.6 내지 1.6mm, 바람직하게는 1.0mm의 메쉬 크기를 갖는 체를 통해 체질함으로써 덩어리를 잘게 부수는 단계; 및
g. 바람직하게 체질된 윤활제를 당해 과립제에 첨가하여, 예를 들면, 큐브 믹서에서 최종 블렌딩하는 단계를 포함한다.
또 다른 공정에서, 단계 (g)에서 최종 블렌딩하기 전에, 붕해제 (예를 들면, 옥수수 전분) 또는 희석제 (예를 들면, 프리젤라틴화 전분) 또는 추가의 붕해제 (크로스포비돈)의 일부와 같은 부형제의 일부를 과립외 (extragranular)에 첨가할 수 있다.
또 다른 버전의 공정에서, 단계 (a) 내지 단계 (e)에서 제조된 과립제를 단일용기 고전단 과립화 공정에서 제조하고 후속적으로 단일용기 과립화기에서 건조시킬 수 있다.
캡슐제의 제조를 위해, 당해 최종 블렌드를 캡슐제 속에 추가로 충전시킨다.
정제 또는 정제 코어를 제조하기 위해, 당해 최종 블렌드를, 적절한 정제 프레스를 사용하여, 적절한 크기 및 파쇄 강도 (crushing strength)를 갖는 목적하는 정제 코어 중량의 정제로 추가로 압착시킨다.
필름-피복 정제를 제조하기 위해, 피복 현탁액을 제조하고, 압착된 정제 코어를, 중량이 약 2 내지 4%, 바람직하게는 약 3% 증가하도록, 표준 필름 피복기를 사용하여 피복 현탁액으로 피복한다. 필름 피복 용매는 휘발성 성분이며, 이는 최종 생성물 중에 잔류하지 않는다. 정제 중의 윤활제의 필요량을 감소시키기 위해, 임의로 외부 윤활 시스템을 사용한다.
실시예 1 - 직접 압착용 제형
스테아르산마그네슘을 제외한 모든 기타 부형제 및 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분을 고전단 블렌더에서 블렌딩한다. 당해 프리믹스를 1mm 체를 통해 체질한다. 스테아르산마그네슘을 첨가한 후에, 당해 프리믹스를 자유 낙하 블렌더로 블렌딩하여 최종 블렌드를 수득한다. 당해 최종 블렌드를 적합한 정제 프레스를 사용하여 정제로 압착한다. 다음의 조성물을 수득할 수 있다.
Figure pat00015
Figure pat00016
실시예 2 - 또 다른 직접 압착용 제형
스테아르산마그네슘을 제외한 모든 기타 부형제 및 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분을 고전단 블렌더에서 블렌딩한다. 당해 프리믹스를 1mm 체를 통해 체질한다. 스테아르산마그네슘을 첨가한 후에, 당해 프리믹스를 자유 낙하 블렌더로 블렌딩하여 최종 블렌드를 수득한다. 당해 최종 블렌드를 적합한 정제 프레스를 사용하여 정제로 압착한다. 다음의 조성물을 수득할 수 있다.
Figure pat00017
Figure pat00018
실시예 3 - 정제 제형
코포비돈을 상온에서 정제수에 용해시켜, 과립화 액체를 제조한다. 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분, 만니톨 및 일부의 프리젤라틴화 전분을 적합한 믹서에서 블렌딩하여, 프리믹스를 제조한다. 당해 프리믹스를 과립화 액체로 습윤시키고 후속적으로 과립화시킨다. 당해 습윤 과립제를 1.6 내지 3.0mm의 메쉬 크기를 갖는 체를 통해 임의로 체질한다. 당해 과립제를, 적합한 건조기에서 약 55℃에서, 건조시 잔류 수분 함량이 2 내지 5% 줄어들 정도로 건조시킨다. 당해 건조된 과립제를 1.0mm의 메쉬 크기를 갖는 체를 통해 임의로 체질한다. 당해 과립제를 적합한 믹서에서 일부의 프리젤라틴화 전분과 블렌딩한다. 디럼핑을 위해 1.0mm 체를 통과시킨 후, 당해 블렌드에 스테아르산마그네슘을 첨가한다. 후속적으로 당해 최종 블렌드를 적합한 믹서에서 최종 블렌딩하여 제조하고, 정제로 압착한다. 다음의 정제 조성물을 수득할 수 있다.
Figure pat00019
실시예 4 - 피복된 정제 제형
코포비돈을 상온에서 정제수에 용해시켜, 과립화 액체를 제조한다. 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분, 만니톨, 프리젤라틴화 전분 및 옥수수 전분을 적합한 믹서에서 블렌딩하여, 프리믹스를 제조한다. 당해 프리믹스를 과립화 액체로 습윤시키고 후속적으로 과립화시킨다 고전단 믹서를 사용하여. 당해 습윤 과립제를 1.6 내지 3.0mm의 메쉬 크기를 갖는 체를 통해 임의로 체질한다. 당해 과립제를 유동층 건조기에서 약 60℃에서, 2 내지 4%의 목적하는 건조 감량이 수득될 때까지 건조시킨다. 당해 최종 블렌드를 정제 코어로 압착한다.
하이드록시프로필 메틸셀룰로오스, 폴리에틸렌 글리콜, 활석, 이산화티탄 및산화철을 적합한 믹서에서 상온에서 정제수에 현탁시켜, 피복 현탁액을 제조한다. 당해 정제 코어를 중량이 약 3% 증가하도록 피복 현탁액으로 피복하여, 필름-피복 정제를 제조한다. 다음의 정제 조성물을 수득할 수 있다.
Figure pat00020
실시예 5 - 정제 제형
코포비돈을 상온에서 정제수에 용해시켜, 과립화 액체를 제조한다. 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분, 만니톨 및 프리젤라틴화 전분을 적합한 믹서에서 블렌딩하여, 프리믹스를 제조한다. 당해 프리믹스를 과립화 액체로 습윤시키고 후속적으로 과립화시킨다. 당해 습윤 과립제를 적합한 체를 통해 임의로 체질한다. 당해 과립제를 적합한 건조기에서 약 50℃에서, 3 내지 5%의 목적하는 건조 감량이 수득될 때까지 건조시킨다. 당해 건조된 과립제를 1.0mm의 메쉬 크기를 갖는 체를 통해 임의로 체질한다.
스테아르산마그네슘을 1.0mm 체를 통과시키고, 과립제를 첨가한다. 후속적으로, 적합한 블렌더에서 최종적으로 블렌딩하여 최종 블렌드를 수득하고, 당해 최종 블렌드를 정제로 압착한다. 다음의 정제 조성물을 수득할 수 있다.
Figure pat00021
실시예 6 - 정제 제형 변형체
코포비돈을 상온에서 정제수에 용해시켜, 과립화 액체를 제조한다. 1급 아미노 그룹을 갖는 활성 DPP IV 억제제 성분 및 일부의 만니톨, 프리젤라틴화 전분 및 옥수수 전분을 적합한 믹서에서 블렌딩하여, 프리믹스를 제조한다. 당해 프리믹스를 과립화 액체로 습윤시키고 후속적으로 과립화시킨다. 당해 습윤 과립제를 적합한 체를 통해 임의로 체질한다. 당해 과립제를 유동층 건조기에서 약 60℃ 불활성 공기 온도에서, 1 내지 4%의 목적하는 건조 감량이 수득될 때까지 건조시킨다. 당해 건조된 과립제를 1.0mm의 메쉬 크기를 갖는 체를 통해 임의로 체질한다.
스테아르산마그네슘 덩어리를 잘게 부수기 위해 체를 통과시킨 후, 당해 과립제에 첨가한다. 추가로, 당해 공정 단계에서 잔류하는 일부의 부형제를 과립 상태 이후에 첨가한다. 후속적으로, 적합한 블렌더에서 최종 블렌딩하에 최종 블렌드를 제조하고, 정제 코어로 압착한다.
하이드록시프로필 메틸셀룰로오스, 폴리에틸렌 글리콜, 활석, 이산화티탄 및산화철을 적합한 믹서에서 상온에서 정제수에 현탁시켜, 피복 현탁액을 제조한다. 중량이 약 3% 증가하도록 당해 정제 코어를 피복 현탁액으로 피복하여, 필름-피복 정제를 제조한다. 다음의 제형 변형체를 수득할 수 있다.
실시예 6.1 - 과립 상태 이후에 부형제를 갖는 제형 변형체
Figure pat00022
실시예 6.2 - 추가의 과립 상태 이후에 붕해제를 갖는 제형 변형체
Figure pat00023
실시예 6.3 - 고용량 제형 D
Figure pat00024

Claims (20)

  1. 활성 성분으로서 아미노 그룹을 갖는 DPP IV (dipeptidyl peptidase IV) 억제제 화합물 또는 이의 염, 제1 희석제, 제2 희석제, 결합제, 붕해제 및 윤활제를 포함하는 약제학적 조성물.
  2. 제1항에 있어서, 추가의 붕해제를 포함하는, 약제학적 조성물.
  3. 제1항 또는 제2항에 있어서, 추가의 활제를 포함하는, 약제학적 조성물.
  4. 제1항에 있어서, 희석제가 셀룰로오스 분말, 2염기성 인산칼슘 무수물, 이염기성 인산칼슘 2수화물, 에리트리톨, 저치환된 하이드록시프로필 셀룰로오스, 만니톨, 프리젤라틴화 전분 또는 자일리톨인, 약제학적 조성물.
  5. 제1항에 있어서, 윤활제가 활석, 폴리에틸렌글리콜, 베헨산칼슘, 스테아르산칼슘, 수소화 피마자유 또는 스테아르산마그네슘인, 약제학적 조성물.
  6. 제2항에 있어서, 결합제가 코포비돈 (비닐피롤리돈의 다른 비닐유도체와의 공중합물), 하이드록시프로필 메틸셀룰로오스 (HPMC), 하이드록시프로필셀룰로오스 (HPC) 또는 폴리비닐피롤리돈 (포비돈)인, 약제학적 조성물.
  7. 제1항에 있어서, 붕해제가 옥수수 전분인, 약제학적 조성물.
  8. 제2항에 있어서, 추가의 붕해제가 크로스포비돈인, 약제학적 조성물.
  9. 제1항에 있어서, 임의의 활제가 콜로이드성 이산화규소인, 약제학적 조성물.
  10. 제1항에 있어서, 제1 희석제가 만니톨이고, 제2 희석제가 프리젤라틴화 전분이고, 결합제가 코포비돈이고, 붕해제가 옥수수 전분이고, 윤활제가 스테아르산마그네슘인, 약제학적 조성물.
  11. 제1항에 있어서, 0.5 내지 20 중량%의 활성 성분, 40 내지 88 중량%의 제1 희석제, 3 내지 40 중량%의 제2 희석제, 1 내지 5 중량%의 결합제, 5 내지 15 중량%의 붕해제 및 0.1 내지 4 중량%의 윤활제를 포함하는, 약제학적 조성물.
  12. 제1항에 있어서, 0.5 내지 7 중량%의 활성 성분, 50 내지 75 중량%의 제1 희석제, 5 내지 15 중량%의 제2 희석제, 2 내지 4 중량%의 결합제, 8 내지 12 중량%의 붕해제 및 0.5 내지 2 중량%의 윤활제를 포함하는, 약제학적 조성물.
  13. 제1항에 있어서, 캡슐, 정제 또는 필름-피복 정제의 투여 제형인, 약제학적 조성물.
  14. 제13항에 있어서, 2 내지 4 중량%의 필름 피복물을 포함하는, 약제학적 조성물.
  15. 제1항에 있어서, 필름 피복물이 필름-형성제, 가소제, 활제 및 임의로 하나 이상의 안료를 포함하는, 약제학적 조성물.
  16. 제15항에 있어서, 필름 피복물이 하이드록시프로필메틸셀룰로오스 (HPMC), 폴리에틸렌 글리콜 (PEG), 활석, 이산화티탄 및 산화철을 포함하는, 약제학적 조성물.
  17. a. 결합제를 용매에 용해시켜, 과립화 액체를 제조하는 단계;
    b. DPP IV 억제제, 희석제 및 붕해제를 블렌딩하여, 프리믹스(pre-mix)를 제조하는 단계;
    c. 상기 프리믹스를 과립화 액체로 습윤시키고, 후속적으로 상기 습윤된 프리믹스를 과립화시는 단계;
    d. 상기 과립화된 프리믹스를 1.0mm 이상의 메쉬 크기를 갖는 체(sieve)를 통해 임의로 체질하는 단계;
    e. 상기 과립제를 약 40 내지 75℃에서, 1 내지 5% 범위의 목적하는 건조 감량이 수득될 때까지 건조시키는 단계;
    f. 상기 건조된 과립제를 0.6mm 이상의 메쉬 크기를 갖는 체를 통해 체질하는 단계; 및
    g. 윤활제를 상기 과립제에 첨가하여 최종 블렌딩하는 단계
    를 포함하는, 제1항에 따르는 약제학적 조성물의 제조방법.
  18. 제17항에 있어서,
    h. 상기 최종 블렌드를 정제 코어로 압착하는 단계;
    i. 피복 현탁액을 제조하는 단계; 및
    j. 중량이 약 2 내지 4% 증가하도록 상기 정제 코어를 피복 현탁액으로 피복하여 필름-피복 정제를 제조하는 단계
    를 추가로 포함하는, 제조방법.
  19. 제17항에 있어서, 단계 g의 최종 블렌딩 이전에, 일부의 부형제가 과립외(extragranular)에 첨가되는, 제조방법.
  20. 제17항에 있어서, 단계 a 내지 단계 e에서 제조된 과립제가 단일용기 고전단 과립화 공정에서 제조되고, 후속적으로 단일용기 과립화기에서 건조되는, 제조방법.
KR1020177035865A 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형 KR102051281B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06009201.2 2006-05-04
EP06009201A EP1852108A1 (en) 2006-05-04 2006-05-04 DPP IV inhibitor formulations
PCT/EP2007/054204 WO2007128724A1 (en) 2006-05-04 2007-04-30 Dpp iv inhibitor formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167029877A Division KR101855323B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형

Publications (2)

Publication Number Publication Date
KR20170141812A true KR20170141812A (ko) 2017-12-26
KR102051281B1 KR102051281B1 (ko) 2019-12-03

Family

ID=36972901

Family Applications (5)

Application Number Title Priority Date Filing Date
KR20087026969A KR101478983B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020157022377A KR101710881B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020147011768A KR20140063896A (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020177035865A KR102051281B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020167029877A KR101855323B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR20087026969A KR101478983B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020157022377A KR101710881B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형
KR1020147011768A KR20140063896A (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167029877A KR101855323B1 (ko) 2006-05-04 2007-04-30 Ｄｐｐ ｉｖ 억제제 제형

Country Status (37)

Country Link
US (8) US20080107731A1 (ko)
EP (5) EP1852108A1 (ko)
JP (7) JP5478244B2 (ko)
KR (5) KR101478983B1 (ko)
CN (2) CN102526737B (ko)
AR (2) AR060755A1 (ko)
AT (1) ATE480228T1 (ko)
AU (1) AU2007247193B2 (ko)
BR (2) BRPI0711179B1 (ko)
CA (1) CA2649922C (ko)
CL (2) CL2012002521A1 (ko)
CY (2) CY1111354T1 (ko)
DE (1) DE602007009091D1 (ko)
DK (3) DK2277509T5 (ko)
EA (2) EA029890B1 (ko)
EC (1) ECSP088800A (ko)
ES (3) ES2527409T4 (ko)
HK (2) HK1172549A1 (ko)
HR (2) HRP20100507T1 (ko)
HU (1) HUE025210T2 (ko)
IL (2) IL195030A (ko)
ME (2) ME01941B (ko)
MX (2) MX2008013958A (ko)
MY (2) MY146969A (ko)
NO (1) NO343067B1 (ko)
NZ (3) NZ613426A (ko)
PE (2) PE20080698A1 (ko)
PL (3) PL2283819T3 (ko)
PT (2) PT2023902E (ko)
RS (2) RS53570B1 (ko)
SG (1) SG171649A1 (ko)
SI (2) SI2283819T1 (ko)
TW (2) TWI520753B (ko)
UA (1) UA94942C2 (ko)
UY (1) UY30319A1 (ko)
WO (1) WO2007128724A1 (ko)
ZA (1) ZA200808361B (ko)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
WO2009073210A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102186474A (zh) * 2008-08-14 2011-09-14 杏林制药株式会社 稳定的医药组合物
WO2010018217A2 (en) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2010038695A1 (ja) * 2008-09-30 2010-04-08 大洋薬品工業株式会社 圧縮成型製剤およびその製造方法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
PE20110834A1 (es) 2008-12-06 2011-12-14 Intra Cellular Therapies Inc DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
US8404727B2 (en) 2009-01-07 2013-03-26 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
TR201905423T4 (tr) 2009-05-19 2019-05-21 Celgene Corp 4-amino-2-(2,6-dioksopiperidin-3-il)izindolin-1,3-dion'un formülasyonları
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
EP2483286B1 (en) 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
KR101763659B1 (ko) 2009-10-02 2017-08-01 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ―1356 및 메트포르민을 포함하는 약제학적 조성물
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9572806B2 (en) 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5031054B2 (ja) * 2010-03-18 2012-09-19 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及びこれを含む固形製剤
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
EP2566464A1 (en) * 2010-05-05 2013-03-13 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising pioglitazone and linagliptin
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8785455B2 (en) 2011-05-10 2014-07-22 Sandoz Ag Polymorph of linagliptin benzoate
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
HUE043540T2 (hu) 2011-07-15 2019-08-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854824A1 (en) 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
CA2874820C (en) 2012-06-05 2020-06-09 Takeda Pharmaceutical Company Limited Disintegrable and preservation stable solid preparation
WO2014026939A1 (en) 2012-08-13 2014-02-20 Sandoz Ag Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
WO2014045266A1 (en) 2012-09-24 2014-03-27 Ulf Eriksson Treatment of type 2 diabetes and related conditions
JP6309895B2 (ja) * 2012-09-27 2018-04-11 株式会社三和化学研究所 アナグリプチン含有製剤
JP6283314B2 (ja) * 2012-09-27 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
WO2014051024A1 (ja) * 2012-09-27 2014-04-03 株式会社 三和化学研究所 アナグリプチン含有医薬組成物
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
WO2014080384A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of linagliptin
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
EP2848242A1 (en) 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of Linagliptin
TR201310724A2 (tr) 2013-09-12 2015-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Linagliptinin farmasotik formulasyonları.
EP2848241A1 (en) 2013-09-12 2015-03-18 Sanovel Ilac Sanayi ve Ticaret A.S. Effervescent formulations of linagliptin
WO2015110962A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and linagliptin or salts thereof
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US20150283248A1 (en) * 2014-04-02 2015-10-08 Aurobindo Pharma Ltd. Pharmaceutical compositions of Linagliptin and process for preparation thereof
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN105878349A (zh) * 2014-11-28 2016-08-24 于凯 一种预防和治疗糖尿病引起的骨质疏松的组合物
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
EP3310357A1 (en) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Alogliptin formulation
US10668073B2 (en) 2015-10-09 2020-06-02 Hexal Ag Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets
US9727330B2 (en) * 2015-11-25 2017-08-08 Red Hat, Inc. Source to image transformation pipeline for a platform-as-a-service system
CN105853382B (zh) * 2016-05-19 2019-07-19 广州迈达康医药科技有限公司 一种利格列汀口崩片及其制备方法
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN106236754A (zh) * 2016-07-31 2016-12-21 合肥远志医药科技开发有限公司 一种包含利格列汀活性成分的组合物及其制备方法
CN106137991A (zh) * 2016-08-01 2016-11-23 合肥远志医药科技开发有限公司 一种利格列汀片制粒方法
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
EP3801539A4 (en) * 2018-06-01 2022-02-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF LINAGLIPTIN
EP4045048A4 (en) 2019-10-14 2023-05-24 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
WO2021109970A1 (zh) * 2019-12-02 2021-06-10 成都苑东生物制药股份有限公司 一种黄嘌呤衍生物药物组合物及其制备方法
CN117858703A (zh) 2021-07-22 2024-04-09 新梅斯托克公司 用于制备包含利格列汀和盐酸二甲双胍的药物组合物的方法
KR20230126664A (ko) 2022-02-23 2023-08-30 주식회사 제뉴원사이언스 리나글립틴 또는 이의 약학적으로 허용가능한 염과 메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 약물방출이 조절된 약제학적 복합제제
CN115227661B (zh) * 2022-09-22 2022-12-13 北京惠之衡生物科技有限公司 一种利格列汀片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR20050058375A (ko) * 2002-08-21 2005-06-16 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-[3-아미노-피페리딘-1-일]-크산틴, 이의 제조방법 및 약제로서의 이의 용도
US20050266080A1 (en) * 2004-05-28 2005-12-01 Desai Divyakant S Coated tablet formulation and method

Family Cites Families (469)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US2375138A (en) * 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
US2629736A (en) * 1951-02-24 1953-02-24 Searle & Co Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
US2730544A (en) * 1952-07-23 1956-01-10 Sahyun Lab Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
US2750387A (en) * 1953-11-25 1956-06-12 Searle & Co Basically substituted derivatives of diarylaminobenzamides
DE1211359B (de) * 1955-11-29 1966-02-24 Oreal Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
US2928833A (en) * 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3673241A (en) * 1968-04-04 1972-06-27 Ciba Geigy Corp Substituted benzaldehyde guanylhydrazones
ES385302A1 (es) 1970-10-22 1973-04-16 Miquel S A Lab Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
DE2205815A1 (de) 1972-02-08 1973-08-16 Hoechst Ag Piperazinderivate und verfahren zu ihrer herstellung
JPS5512435B2 (ko) * 1972-07-01 1980-04-02
US4005208A (en) * 1975-05-16 1977-01-25 Smithkline Corporation N-Heterocyclic-9-xanthenylamines
US4061753A (en) 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
AU508480B2 (en) 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2758025A1 (de) 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2929596A1 (de) 1979-07-21 1981-02-05 Hoechst Ag Verfahren zur herstellung von oxoalkyl-xanthinen
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
US4382091A (en) 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
FR2558162B1 (fr) * 1984-01-17 1986-04-25 Adir Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
JPS6130567A (ja) 1984-07-23 1986-02-12 Shiseido Co Ltd 尿素の安定化法
JPS61124383A (ja) 1984-11-16 1986-06-12 Unitika Ltd 固定化線維素溶解活性酵素の安定化法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
CA1242699A (en) 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
US5258380A (en) * 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
ES2058061T3 (es) 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
US5034225A (en) 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DE3683760D1 (de) 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
ATE110083T1 (de) 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
AU619444B2 (en) 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
EP0342675B1 (en) 1988-05-19 1995-01-25 Chugai Seiyaku Kabushiki Kaisha Novel quinolonecarboxylic acid derivatives
US5329025A (en) * 1988-09-21 1994-07-12 G. D. Searle & Co. 3-azido compound
DE3926119A1 (de) 1989-08-08 1991-02-14 Bayer Ag 3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
US5234897A (en) * 1989-03-15 1993-08-10 Bayer Aktiengesellschaft Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE3916430A1 (de) 1989-05-20 1990-11-22 Bayer Ag Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5223499A (en) * 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU208115B (en) 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
ES2084801T3 (es) * 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
ATE112491T1 (de) 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5084460A (en) * 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
DE4124150A1 (de) 1991-07-20 1993-01-21 Bayer Ag Substituierte triazole
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
ATE165360T1 (de) 1992-07-31 1998-05-15 Shionogi & Co Triazolylthiomethylthiocephalosporin- hydrochlorid, sein kristallines hydrat und seine herstellung
TW252044B (ko) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
DE4242459A1 (de) * 1992-12-16 1994-06-23 Merck Patent Gmbh Imidazopyridine
AU6087894A (en) 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
JP3726291B2 (ja) 1993-07-05 2005-12-14 三菱ウェルファーマ株式会社 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
FR2707641B1 (fr) 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
DE4339868A1 (de) 1993-11-23 1995-05-24 Merck Patent Gmbh Imidazopyridazine
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5545745A (en) 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
WO1996011917A1 (en) 1994-10-12 1996-04-25 Euro-Celtique, S.A. Novel benzoxazoles
GB9501178D0 (en) 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2218548A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
JPH08333339A (ja) 1995-06-08 1996-12-17 Fujisawa Pharmaceut Co Ltd 光学活性なピペリジン酢酸誘導体の製造法
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19543478A1 (de) 1995-11-22 1997-05-28 Bayer Ag Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
FR2742751B1 (fr) 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997023447A1 (en) 1995-12-26 1997-07-03 Alteon Inc. N-acylaminoalkylhydrazinecarboximidamides
US5891855A (en) 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5965555A (en) 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US5958951A (en) 1996-06-14 1999-09-28 Novo Nordiskials Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
EA001881B1 (ru) 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
WO1998018770A1 (en) 1996-10-28 1998-05-07 Novo Nordisk A/S A process for the preparation of (-)-3,4-trans-diarylchromans
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
EE04266B1 (et) 1996-12-24 2004-04-15 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon
DE19705233A1 (de) 1997-02-12 1998-08-13 Froelich Juergen C Verfahren zur Herstellung einer Formulierung enthaltend Arginin
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
DK0991407T4 (da) 1997-03-13 2005-08-08 Hexal Ag Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
TR200001603T2 (tr) * 1997-12-05 2000-10-23 Astrazeneca Uk Limited Yeni bileşikler
ID21411A (id) 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
JPH11193270A (ja) 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
CA2315736A1 (en) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
US20030013740A1 (en) 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
JP2002509919A (ja) 1998-03-31 2002-04-02 日産化学工業株式会社 ピリダジノン化合物塩酸塩及びその製造法
CA2268621A1 (en) 1998-04-13 1999-10-13 Takeda Chemical Industries, Ltd. 2-pipirazinone-1-acetic acid derivative, production and use thereof
US6207207B1 (en) 1998-05-01 2001-03-27 Mars, Incorporated Coated confectionery having a crispy starch based center and method of preparation
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
WO2000003735A1 (fr) 1998-07-15 2000-01-27 Asahi Kasei Kogyo Kabushiki Kaisha Excipient
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IT1312018B1 (it) 1999-03-19 2002-04-04 Fassi Aldo Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
WO2000066101A2 (en) 1999-04-30 2000-11-09 City Of Hope Method of inhibiting glycation product formation
AU4431000A (en) 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
WO2000072799A2 (en) 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
CN100448482C (zh) 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
WO2000072973A1 (en) 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
YU90901A (sh) 1999-06-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
SG149676A1 (en) 1999-12-23 2009-02-27 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
WO2001051919A2 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
ES2436610T3 (es) 2000-01-21 2014-01-03 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
JP4621326B2 (ja) * 2000-02-01 2011-01-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 テプレノンの安定化組成物
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU2001234114A1 (en) 2000-02-24 2001-09-03 Takeda Chemical Industries Ltd. Drugs containing combined active ingredients
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
JP2001278812A (ja) * 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
DK2055302T3 (da) 2000-03-31 2014-10-27 Royalty Pharma Collection Trust Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf
US7282219B2 (en) 2000-03-31 2007-10-16 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
JP2001292388A (ja) 2000-04-05 2001-10-19 Sharp Corp 再生装置
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
WO2001096301A1 (fr) 2000-06-14 2001-12-20 Toray Industries, Inc. Procedes de production de derive de piperidine racemique et de production de derive de piperidine a activite optique
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
MXPA02012272A (es) 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
EP1950199B1 (en) * 2000-08-10 2009-12-02 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20060034922A1 (en) 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6722883B2 (en) 2000-11-13 2004-04-20 G & H Technologies Llc Protective coating for abrasive dental tools and burs
US6821261B2 (en) 2000-12-12 2004-11-23 Dj Orthopedics, Llc Orthopedic brace having length-adjustable supports
JPWO2002051836A1 (ja) 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
FR2818906B1 (fr) 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
FR2819254B1 (fr) 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
DE10117803A1 (de) 2001-04-10 2002-10-24 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10109021A1 (de) 2001-02-24 2002-09-05 Boehringer Ingelheim Pharma Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
PL364221A1 (en) 2001-02-02 2004-12-13 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
WO2002066015A1 (en) 2001-02-16 2002-08-29 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2002348279A (ja) 2001-05-25 2002-12-04 Nippon Kayaku Co Ltd 光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
IL158923A0 (en) 2001-06-27 2004-05-12 Smithkline Beecham Corp Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7085258B2 (en) * 2001-07-19 2006-08-01 International Business Machines Corporation Instant messaging with voice conversation feature
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
TWI246510B (en) 2001-09-14 2006-01-01 Mitsubishi Pharma Corp Thiazolidine derivatives and pharmaceutical uses thereof
WO2003024965A2 (en) * 2001-09-19 2003-03-27 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
DK1435877T3 (da) 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
DE10151296A1 (de) 2001-10-17 2003-04-30 Boehringer Ingelheim Pharma Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
KR20040064687A (ko) 2001-12-21 2004-07-19 도오레 화인케미칼 가부시키가이샤 광학 활성 시스 피페리딘 유도체의 제조법
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
WO2003057245A1 (fr) 2001-12-28 2003-07-17 Nrl Pharma, Inc. Compositions servant a ameliorer le metabolisme lipidique
WO2003057200A2 (en) 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US20070197552A1 (en) 2002-01-11 2007-08-23 Novo Nordisk A/S Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
EP1854454B1 (en) 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan
EP1477182A4 (en) 2002-01-21 2009-05-27 Nrl Pharma Inc NEW ANALGETICS
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
JP2005517690A (ja) * 2002-02-01 2005-06-16 ファイザー・プロダクツ・インク 固体薬物分散物を含有する即時放出剤形
US7610153B2 (en) 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
SI1476138T1 (sl) 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JP4298212B2 (ja) 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
JP2003300977A (ja) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd キサンチン誘導体
EP1496982A4 (en) 2002-04-16 2006-07-19 Merck & Co Inc SOLID FORMS OF SALTS WITH TYROSINE KINASE EFFECT
CA2484306A1 (en) 2002-04-26 2003-11-06 Katsumi Maezono Prophylactic and therapeutic agent of diabetes mellitus
AU2003231252A1 (en) 2002-05-09 2003-11-11 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
GB0212412D0 (en) 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
DK1509525T5 (da) 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
BR0311697A (pt) 2002-06-06 2005-03-22 Eisai Co Ltd Novos derivados condensados de imidazol
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
US20040002615A1 (en) 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
US7065367B2 (en) * 2002-07-11 2006-06-20 Oliver Michaelis Interface selection in a wireless communication network
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
AR040661A1 (es) 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
TW200404796A (en) 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
DE10238243A1 (de) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
JP2004123738A (ja) * 2002-09-11 2004-04-22 Takeda Chem Ind Ltd 徐放性製剤
CN1688293A (zh) * 2002-09-16 2005-10-26 韦思公司 多肽治疗剂口服给药的缓释配方及其使用方法
AU2003266559B2 (en) * 2002-09-26 2008-01-24 Eisai R&D Management Co., Ltd. Combination drug
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20040122048A1 (en) 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
JP4352001B2 (ja) 2002-10-18 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療または予防のためのベータ−アミノ複素環式ジペプチジルペプチダーゼ阻害剤
JP2004161749A (ja) 2002-10-24 2004-06-10 Toray Fine Chemicals Co Ltd 光学活性含窒素化合物の製造方法
WO2004048379A1 (ja) 2002-11-01 2004-06-10 Sumitomo Pharmaceuticals Co., Ltd. キサンチン化合物
RU2005117383A (ru) 2002-11-07 2006-01-20 Мерк энд Ко., Инк. (US) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
ATE404191T1 (de) 2002-12-10 2008-08-15 Novartis Pharma Ag Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist
DE10351663A1 (de) 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
US20040152720A1 (en) 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004250336A (ja) * 2003-02-18 2004-09-09 Kao Corp コーティング錠及び糖衣錠の製造法
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
CA2515289A1 (en) 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Weak base salts
CN100415224C (zh) 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004096806A1 (ja) 2003-04-30 2004-11-11 Sumitomo Pharmaceuticals Co. Ltd. 縮合イミダゾール誘導体
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
AU2003902828A0 (en) 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
MXPA05013734A (es) 2003-06-20 2006-03-08 Hoffmann La Roche Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
DE602004030244D1 (de) 2003-06-20 2011-01-05 Hoffmann La Roche Itoren
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
US7364755B2 (en) 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050027012A1 (en) 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
US20060134206A1 (en) 2003-07-24 2006-06-22 Iyer Eswaran K Oral compositions for treatment of diseases
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
CN1829709A (zh) * 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN102349927A (zh) * 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20070072810A1 (en) 2003-10-03 2007-03-29 Takeda Pharmaceutical Company, Limited Agent for treating diabetes
US7107714B2 (en) 2003-11-10 2006-09-19 Marketing Displays, Inc. Portable snap-fit sign stand
KR20140089408A (ko) 2003-11-17 2014-07-14 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JPWO2005053695A1 (ja) * 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 多発性硬化症予防剤または治療剤
US7217711B2 (en) * 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
ATE501135T1 (de) * 2003-12-18 2011-03-15 Tibotec Pharm Ltd Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
CA2549955A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
EP1708680A2 (en) 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
PT1758905E (pt) 2004-02-18 2009-07-16 Boehringer Ingelheim Int 8-[3-amino-piperidin-1-il]-xantinas, sua preparação e sua utilização como inibidores de dpp-iv
DE102004019540A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
US7393847B2 (en) * 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
EA011158B1 (ru) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2005097798A1 (de) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US20050244502A1 (en) 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
CN1976691B (zh) 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
US20050276794A1 (en) 2004-06-09 2005-12-15 Papas Klearchos K Composition and method for improving pancreatic islet cell survival
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
CA2511269A1 (en) 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
CA2573209A1 (en) 2004-07-14 2006-01-19 Novartis Ag Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
JP2006045156A (ja) 2004-08-06 2006-02-16 Sumitomo Pharmaceut Co Ltd 縮合ピラゾール誘導体
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
EP1782832A4 (en) 2004-08-26 2009-08-26 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF DIABETES
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CA2580461A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
BRPI0516446A (pt) 2004-10-08 2008-09-02 Novartis Ag combinação de compostos orgánicos
EA013463B1 (ru) 2004-10-12 2010-04-30 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Новые ингибиторы дипептидилпептидазы iv, содержащие их фармацевтические композиции, способ их получения и способ лечения с их применением
MX2007004934A (es) 2004-10-25 2007-06-12 Novartis Ag Combinacion de inhibidor de dpp-iv, anti-diabetico de ppar, y metformina.
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2006137678A (ja) 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
BRPI0518651A2 (pt) 2004-12-24 2008-12-02 Dainippon Sumitomo Pharma composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
KR100760430B1 (ko) 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
EP1874339A1 (en) 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CN101203494A (zh) 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
EP1894567B1 (en) 2005-06-03 2012-08-15 Mitsubishi Tanabe Pharma Corporation Concomitant pharmaceutical agents and use thereof
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
NZ564285A (en) 2005-06-20 2010-03-26 Decode Genetics Ehf Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
ATE483732T1 (de) 2005-07-08 2010-10-15 Pfizer Ltd Madcam-antikörper
UY29694A1 (es) 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008001799A (es) * 2005-08-11 2008-04-16 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
PL1931350T5 (pl) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
RS20080112A (en) 2005-09-16 2009-05-06 Arena Pharmaceuticals Inc., Modulators of metabolism and the treatment of disorders related thereto
RU2440143C2 (ru) 2005-09-20 2012-01-20 Новартис Аг Применение ингибитора dpp-iv для снижения приступов гликемии
WO2007038979A1 (en) 2005-09-22 2007-04-12 Swissco Development Ag Effervescent metformin composition and tablets and granules made therefrom
JOP20180109A1 (ar) 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
US20080221200A1 (en) 2005-09-30 2008-09-11 Malcolm Allison Combination of Organic Compounds
CA2625646A1 (en) 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
CN101300298A (zh) 2005-11-04 2008-11-05 Ls电线有限公司 Mdh-聚合物混合粒子的合成
EP1962827A4 (en) 2005-12-16 2011-02-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN
JP2009520763A (ja) 2005-12-23 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤として有用な縮合ヘテロ環式化合物
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090054512A1 (en) 2006-01-06 2009-02-26 Foley James E Use of organic compounds
KR20080102395A (ko) 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR20070111099A (ko) 2006-05-16 2007-11-21 영진약품공업주식회사 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
NZ572368A (en) 2006-05-16 2011-04-29 Gilead Sciences Inc Method and compositions for treating hematological malignancies
WO2007137107A2 (en) 2006-05-19 2007-11-29 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
KR100858848B1 (ko) 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
WO2007149797A2 (en) 2006-06-19 2007-12-27 Novartis Ag Use of organic compounds
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
AT503443B1 (de) 2006-06-23 2007-10-15 Leopold Franzens Uni Innsbruck Verfahren zur herstellung einer eisfläche für eissportbahnen
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008017670A1 (en) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
JP5384343B2 (ja) 2006-08-15 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
JP2010501010A (ja) 2006-08-17 2010-01-14 ウェルスタット セラピューティクス コーポレイション 代謝障害のための併用処置
DE102006042586B4 (de) 2006-09-11 2014-01-16 Betanie B.V. International Trading Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
EP2079753A1 (en) 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
US7956201B2 (en) 2006-11-06 2011-06-07 Hoffman-La Roche Inc. Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
JP5337040B2 (ja) 2006-11-09 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ−２インヒビターとの組み合わせ治療及びそれらの医薬組成物
EA015835B1 (ru) 2006-12-06 2011-12-30 Смитклайн Бичем Корпорейшн Производные 4-окса(тиа)метилпиперидина и их применение в качестве противодиабетических средств
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
CL2008000133A1 (es) 2007-01-19 2008-05-23 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
EP2124901B1 (en) 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
ME01239B (me) 2007-02-01 2013-06-20 Takeda Pharmaceuticals Co Čvrsti preparat koji sadrži alogliptin i pioglitazon
ES2366000T3 (es) 2007-02-06 2011-10-14 Chelsea Therapeutics, Inc. Nuevos compuestos, métodos para su preparación y uso de los mismos.
WO2008113000A1 (en) 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
EP2143443B1 (en) 2007-04-03 2014-11-19 Mitsubishi Tanabe Pharma Corporation A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity
WO2008130998A2 (en) 2007-04-16 2008-10-30 Smith & Nephew, Inc. Powered surgical system
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2144902B1 (en) 2007-05-04 2012-05-16 Bristol-Myers Squibb Company [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
WO2007135196A2 (en) 2007-07-09 2007-11-29 Symrise Gmbh & Co. Kg Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0
WO2009011451A1 (en) 2007-07-19 2009-01-22 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
CL2008002424A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
CL2008002425A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UY31291A1 (es) 2007-08-16 2009-03-31 Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido
US20110112069A1 (en) 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2009037719A1 (en) 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
CN101234105A (zh) 2008-01-09 2008-08-06 北京润德康医药技术有限公司 一种含有二甲双胍和维格列汀的药用组合物及其制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US20090186086A1 (en) 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
TW200936136A (en) 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
US20100330177A1 (en) 2008-02-05 2010-12-30 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
CA2716130A1 (en) 2008-03-04 2009-09-11 Nazaneen Pourkavoos Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PL2280704T3 (pl) 2008-03-31 2015-10-30 Cymabay Therapeutics Inc Związki oksymetylenoarylowe i ich zastosowania
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN101590007A (zh) 2008-05-27 2009-12-02 北京瑞伊人科技发展有限公司 一种盐酸二甲双胍/伏格列波糖降糖口服制剂组合物及其制备
PE20100156A1 (es) 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
WO2010018217A2 (en) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
JP2010053576A (ja) 2008-08-27 2010-03-11 Sumitomo Forestry Co Ltd 舗装用マット
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
UY32177A (es) 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EA029759B1 (ru) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
TW201031661A (en) 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
JP2012525396A (ja) 2009-04-27 2012-10-22 レバレジオ コーポレイション インスリン耐性および真性糖尿病を治療するための組成物および方法
US20120100221A1 (en) 2009-06-02 2012-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
AU2010260373A1 (en) 2009-06-15 2012-01-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
EP2456426A1 (en) 2009-07-21 2012-05-30 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
KR101763659B1 (ko) 2009-10-02 2017-08-01 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ―1356 및 메트포르민을 포함하는 약제학적 조성물
JP5446716B2 (ja) 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP2010070576A (ja) 2009-12-28 2010-04-02 Sato Pharmaceutical Co Ltd 速溶解性錠剤
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
EP2566464A1 (en) 2010-05-05 2013-03-13 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising pioglitazone and linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
US9271984B2 (en) 2010-06-09 2016-03-01 Poxel Treatment of type 1 diabetes
AR084698A1 (es) 2010-06-22 2013-06-05 Twi Pharmaceuticals Inc Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012039420A1 (ja) 2010-09-21 2012-03-29 国立大学法人九州大学 動脈圧反射機能障害に関連した疾患を治療するためのバイオニック動脈圧反射システム
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012088682A1 (en) 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
WO2012106303A1 (en) 2011-02-01 2012-08-09 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8785455B2 (en) 2011-05-10 2014-07-22 Sandoz Ag Polymorph of linagliptin benzoate
HUE043540T2 (hu) 2011-07-15 2019-08-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
MX353496B (es) 2012-01-04 2018-01-16 Procter & Gamble Estructuras fibrosas que contienen activos con múltiples regiones.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
EP2854824A1 (en) 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
WO2013179307A2 (en) 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
EP2887961B1 (en) 2012-08-24 2021-04-28 Novartis AG Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
JP2015533134A (ja) 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
WO2014056941A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Use of moisture-conditioned disintegrants in tablet manufacture
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
JP2016518438A (ja) 2013-05-17 2016-06-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＤＰＰ−４阻害薬とα−グルコシダーゼ阻害薬との組合せ
JP6507154B2 (ja) 2013-06-14 2019-04-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN104130258B (zh) 2014-08-13 2016-06-01 广东东阳光药业有限公司 一种二聚体的转化方法
WO2016059219A1 (en) 2014-10-17 2016-04-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR20050058375A (ko) * 2002-08-21 2005-06-16 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-[3-아미노-피페리딘-1-일]-크산틴, 이의 제조방법 및 약제로서의 이의 용도
US20050266080A1 (en) * 2004-05-28 2005-12-01 Desai Divyakant S Coated tablet formulation and method

Also Published As

Publication number Publication date
KR20090009226A (ko) 2009-01-22
JP6987908B2 (ja) 2022-01-05
JP2013227338A (ja) 2013-11-07
EA200802184A1 (ru) 2009-06-30
EP2023902B8 (en) 2010-11-24
KR20140063896A (ko) 2014-05-27
US11033552B2 (en) 2021-06-15
KR20150100957A (ko) 2015-09-02
PT2283819E (pt) 2014-11-03
AU2007247193B2 (en) 2013-05-16
JP2016104811A (ja) 2016-06-09
JP2020079316A (ja) 2020-05-28
PL2023902T3 (pl) 2011-03-31
CY1116064T1 (el) 2017-02-08
KR101855323B1 (ko) 2018-05-09
ECSP088800A (es) 2008-11-27
DE602007009091D1 (de) 2010-10-21
JP2022075826A (ja) 2022-05-18
NZ613426A (en) 2015-02-27
IL195030A0 (en) 2009-08-03
AU2007247193A1 (en) 2007-11-15
ME01170B (me) 2013-03-20
MY148496A (en) 2013-04-30
RS51466B (en) 2011-04-30
CY1111354T1 (el) 2015-08-05
IL195030A (en) 2013-09-30
PT2023902E (pt) 2010-10-12
AR079930A2 (es) 2012-02-29
TW200812648A (en) 2008-03-16
TW201417844A (zh) 2014-05-16
JP5478244B2 (ja) 2014-04-23
PL2023902T4 (pl) 2011-06-30
HUE025210T2 (en) 2016-03-29
KR102051281B1 (ko) 2019-12-03
JP7084711B2 (ja) 2022-06-15
KR101478983B1 (ko) 2015-01-05
US20210260068A1 (en) 2021-08-26
US20130122089A1 (en) 2013-05-16
CN101437493B (zh) 2013-10-23
EP2283819B1 (en) 2014-10-08
HRP20100507T1 (hr) 2010-10-31
TWI474843B (zh) 2015-03-01
EA201100958A1 (ru) 2012-04-30
HK1130442A1 (en) 2009-12-31
RS53570B1 (en) 2015-02-27
EP2023902A1 (en) 2009-02-18
US20080107731A1 (en) 2008-05-08
JP2009535376A (ja) 2009-10-01
JP6100998B2 (ja) 2017-03-22
NO20084256L (no) 2008-12-02
MX2008013958A (es) 2008-11-12
MX358617B (es) 2018-08-29
ES2348576T3 (es) 2010-12-09
PE20080698A1 (es) 2008-08-04
SI2023902T1 (sl) 2011-01-31
EP2023902B1 (en) 2010-09-08
ES2538818T3 (es) 2015-06-24
EP1852108A1 (en) 2007-11-07
EP2283819A1 (en) 2011-02-16
ES2527409T4 (es) 2015-03-11
CA2649922A1 (en) 2007-11-15
AR060755A1 (es) 2008-07-10
US20120003313A1 (en) 2012-01-05
EP2277509B1 (en) 2015-03-11
BRPI0722388B1 (pt) 2022-09-27
DK2283819T3 (da) 2015-01-05
SI2283819T1 (sl) 2015-01-30
EA016559B1 (ru) 2012-05-30
EP2283819B9 (en) 2015-03-11
PL2283819T3 (pl) 2015-03-31
BRPI0722388A2 (pt) 2015-05-19
ME01941B (me) 2015-05-20
NZ595983A (en) 2013-08-30
CL2012002522A1 (es) 2012-12-21
KR101710881B1 (ko) 2017-02-28
CN102526737A (zh) 2012-07-04
JP2012072187A (ja) 2012-04-12
UA94942C2 (ru) 2011-06-25
BRPI0711179B1 (pt) 2022-02-08
BRPI0711179A2 (pt) 2011-05-03
US20190209571A1 (en) 2019-07-11
SG171649A1 (en) 2011-06-29
DK2277509T3 (da) 2015-04-13
EP2910241A1 (en) 2015-08-26
HK1172549A1 (en) 2013-04-26
JP2018021082A (ja) 2018-02-08
US20120219622A1 (en) 2012-08-30
MY146969A (en) 2012-10-15
WO2007128724A1 (en) 2007-11-15
US20160022687A1 (en) 2016-01-28
CL2012002521A1 (es) 2012-12-21
TWI520753B (zh) 2016-02-11
CN101437493A (zh) 2009-05-20
CA2649922C (en) 2014-02-04
HRP20150003T1 (en) 2015-03-13
HRP20150003T2 (hr) 2015-12-18
ES2527409T3 (es) 2015-01-23
DK2023902T3 (da) 2010-11-15
ZA200808361B (en) 2010-10-27
KR20160128446A (ko) 2016-11-07
DK2277509T5 (da) 2015-06-08
NO343067B1 (no) 2018-10-22
UY30319A1 (es) 2008-01-02
PE20110666A1 (es) 2011-09-23
EA029890B1 (ru) 2018-05-31
PL2277509T3 (pl) 2015-07-31
IL212841A0 (en) 2011-07-31
US20170312287A1 (en) 2017-11-02
ATE480228T1 (de) 2010-09-15
JP6564720B2 (ja) 2019-08-21
EP2277509A1 (en) 2011-01-26
CN102526737B (zh) 2015-02-25
NZ572862A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
KR101710881B1 (ko) Ｄｐｐ ｉｖ 억제제 제형
JP2013227338A6 (ja) Ｄｐｐ ｉｖインヒビター製剤
JP2009535376A6 (ja) Ｄｐｐ ｉｖインヒビター製剤

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J206 Request for trial to confirm the scope of a patent right
J206 Request for trial to confirm the scope of a patent right
J204 Request for invalidation trial [patent]
J206 Request for trial to confirm the scope of a patent right
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL NUMBER: 2022100002696; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220928

Effective date: 20230718

Free format text: TRIAL NUMBER: 2022100002695; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220928

Effective date: 20230718

J206 Request for trial to confirm the scope of a patent right
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL NUMBER: 2023100000412; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20230120

Effective date: 20230810

J206 Request for trial to confirm the scope of a patent right
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL NUMBER: 2023100001555; TRIAL DECISION FOR INVALIDATION REQUESTED 20230421

Effective date: 20240220

Free format text: TRIAL NUMBER: 2023100001550; TRIAL DECISION FOR INVALIDATION REQUESTED 20230421

Effective date: 20240220